This meta-analysis looked at data from many studies involving 175,434 people who received dengue vaccines or a placebo. The goal was to see how well the vaccines worked and if they were safe. The researchers found that vaccinated people had a lower rate of viremia, which is the presence of the virus in the blood. They also had a lower rate of hemorrhagic fever, a severe form of dengue. The odds of getting infected were much lower for those who got the vaccine compared to the placebo group.
The vaccines also helped the body produce more antibodies, which are proteins that fight off infections. This suggests the vaccines help the immune system recognize and fight the dengue virus more effectively. The study looked at several secondary outcomes to get a full picture of the vaccine's effects.
Regarding safety, the vaccines caused common side effects like swelling, redness, itching, rash, fatigue, muscle pain, joint pain, general feeling of being unwell, nausea, and low white blood cell counts. However, there was no significant difference in serious adverse events between the vaccine group and the placebo group. The overall tolerability of the vaccines was described as promising based on these results.